Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis.

C LeonardiKim A Papp Bruce E StroberD ThaçiR B WarrenS TyringD ArikanM KarunaratneW C Valdecantos

Published in: The British journal of dermatology (2018)

AE rates remained stable in this analysis of patients with psoriasis receiving adalimumab; no new safety signals were identified compared with earlier analyses.

Keyphrases

clinical trial
rheumatoid arthritis
juvenile idiopathic arthritis
coronary artery disease
early onset
high intensity
atopic dermatitis
randomized controlled trial
systemic lupus erythematosus
disease activity